Subject Matter of the Lobbying Activity
|
Specific Topics of Lobbying Communications
|
Intended Outcomes
|
Associated Subject Matters
|
ADM Moneo was copied on an email to PLBSD senior Formulary Management staff requesting an update on the Drug Review Process status for Kesimpta used to treat Relapsing Remitting Multiple Sclerosis. The email communication requested copies of documents related to Pharmacare's Drug Review Process for Kesimpta (documents requested were; 1) the draft Drug Benefit Council Recommendation, and 2) Clinical Practice Reviews for Kesimpta.) The email request also included the following PDF documents as attachments; a copy of the November 20, 2020 submission cover letter from Novartis to PLBSD requesting Kesimpta be included as a Pharmacare benefit for BC patients with RRMS. The email message also included a PDF copy of the March 2021 CADTH Final Recommendation indicating that provincial drug plans should add Kesimpta as a public drug plan benefit. The message also indicated that all other western provinces have or will soon add Kesimpta as an eligible public drug plan benefit for RRMS. Saskatchewan Drug Plan benefit as of May 1st, Alberta Heath Drug Plan Benefit as of May 1st; Manitoba Provincial Drug Plan Benefit; June 1st (per Manitoba Drug Benefits Formulary Bulletin #118, page 5)
Footnote1
|
- Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
- Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
|
Health
Footnote1
|
ADM Moneo was copied on an email to PLBSD senior Formulary Management staff requesting an update on the Drug Review Process status for Kesimpta used to treat Relapsing Remitting Multiple Sclerosis. The email communication requested copies of documents related to the Pharmacare Drug Review for Kesimpta (i.e. draft Drug Benefit Council Recommendation and Clinical Practice Reviews.) The email request also included attached PDF documents; a copy of the November 20, 2020 submission letter from Novartis to PLBSD requesting inclusion of Kesimpta as a Pharmacare benefit for BC patients with RRMS. Attachments to the email message also included the March 2021 CADTH Final Recommendation indicating that provincial drug plans should add Kesimpta as a public drug plan benefit. The email copied to ADM Moneo indicated that all other western provinces either already have, or are adding Kesimpta as an eligible public drug plan benefit, to treat RRMS (ref. plans covering Kesimpta as follows; Saskatchewan; May 1st, Alberta; May 1st; Manitoba; June 1st (Manitoba Drug Benefits Formulary Bulletin #118, page 5)
Footnote1
|
- Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
- Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
|
Health
Footnote1
|
|